Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoxodiol plus carboplatin versus carboplatin plus placebo in platinum-resistant or platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
2005-006173-27Phase 3Completed
- Sponsor
- MEI Pharma
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Phenoxodiol + carboplatin with Placebo + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started May 2007; status: completed.
02
Drugs
idronoxil
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-006173-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006173-27.